Pfizer’s Phase 3 MagnetisMM-5 trial found that Elrexfio (elranatamab) significantly improved progression-free survival over a standard daratumumab-based regimen in relapsed or refractory multiple ...

Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...

A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...

The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...

Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily ...

Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...

ORLANDO, Fla. — Adding epcoritamab (Epkinly) to the standard-of-care (SOC) therapy of lenalidomide (Revlimid) and rituximab (Rituxan), a combination known as R 2, lowered the risk for disease ...